Clinical trials: Acute Non-Lymphocytic Leukemia
Leukemia, Acute Myeloid Leukemia
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy.
- Conditions
- Leukemia, Acute Myeloid Leukemia, Lymphoblastic Leukemia in Children
- Trial name
- NCT06810583
- Testing
- Dalbavancin, Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid…
- Trial name
- NCT07228273
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial studies the side effects and best dose of vorinostat and azacitidine and to see how well they work in treating patients with myelodysplastic syndromes or acute myeloid leukemia.
- Conditions
- Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00392353
- Testing
- Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 135 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia
Lenalidomide Plus Chemotherapy for AML
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01681537
- Testing
- Lenalidomide, Mitoxantrone, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Acute Myeloid Leukemia
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML).
- Trial name
- NCT00926731
- Testing
- AZD1152, LDAC (low dose cytosine arabinoside)
- Where
- 4 sites in United States, France
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Chronic Myeloproliferative Disorders, Leukemia
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of 506U78 in treating patients who have hematologic cancer…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004239
- Testing
- Compound 506U78
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
The purpose of this study is to evaluate the dose-limiting toxicities (DLT) and define the maximum tolerated dose (MTD) and the recommended phase II study dose of gilteritinib when combined with mitoxantrone, cladribine…
- Trial name
- NCT05330377
- Testing
- Gilteritinib 40 MG Oral Tablet, Cladribine, Cytarabine
- Where
- United States
- Sponsor
- Ayman H Qasrawi
Acute Myeloid Leukemia (AML)
Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of oral azacitidine prescribed as maintenance treatment after frontline…
- Trial name
- RELION (NCT06565975)
- Testing
- Oral azacitidine
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndromes, Myelodysplastic Anemia
Biocollection in MyeloDysplastic Syndrome (P-MDS)
Myelodysplastic syndromes (MDS) are chronic myeloid hemopathies characterized by ineffective hematopoiesis (with peripheral cytopenias) and which contrast with a marrow of normal richness.
- Conditions
- Myelodysplastic Syndromes, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q), Myelodysplastic Syndrome With Ring Sideroblasts
- Trial name
- P-MDS (NCT04869683)
- Testing
- description of MDS pzatient cohort
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Acute Myeloid Leukemia
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Rencent years have witnessed great progress of the treatment of acute myeloid leukemia (AML). However, most patients have poor outcomes following the currently first-line DA(daunorubicin, cytarabine)/IA(Idarubicin, cytarabine)…
- Trial name
- NCT04248595
- Testing
- Homoharringtonine, Azacitidine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ge Zheng
Acute Lymphoblastic Leukemia, ALL
Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Patients are being asked to participate in this study because treatment for their disease requires a stem cell transplant (SCT).
- Conditions
- Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML
- Trial name
- IL2 for GVHD (NCT00539695)
- Testing
- IL-2
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia (AML)
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety, tolerability and potential efficacy of IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia (AML).
- Trial name
- NCT02826642
- Testing
- IDH305
- Sponsor
- Novartis Pharmaceuticals
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult participants who are ineligible for…
- Trial name
- VALOR (NCT05215639)
- Where
- 19 sites in Austria, Switzerland
- Volunteers
- 120 people
- Sponsor
- AbbVie
Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
The purpose of Part 1 (Dose Escalation) of the study is to assess the safety and tolerability, and to identify the recommended Phase 2 dose[s] (RP2D[s]) in participants with relapsed or refractory (R/R) acute myeloid leukemia…
- Trial name
- NCT06618001
- Testing
- JNJ-89853413
- Where
- 9 sites in Canada, Spain and 1 more
- Volunteers
- 64 people
- Sponsor
- Janssen Research & Development, LLC
ACUTE MYELOID LEUKEMIA
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or…
- Trial name
- NCT04051996
- Testing
- Glasdegib, Decitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
This phase I trial is studying the side effects and best dose of GTI-2040 and high-dose cytarabine in treating patients with refractory or relapsed acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00070551
- Testing
- GTI-2040, cytarabine, pharmacological study
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
This is a single-center, prospective, exploratory clinical study. It plans to enroll 30 adult patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR1) after induction therapy and meet the…
- Trial name
- NCT07644481
- Testing
- CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA).
- Trial name
- VIALE-M (NCT04102020)
- Testing
- Venetoclax, Azacitidine
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 112 people
- Sponsor
- AbbVie
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.